Contemporary Clinical Management of Endometrial Cancer

<table class="table-group" id="tab11"><tr><td><table class="table"><tr><td class="thead-hr" colspan="2"><hr/></td></tr><tr class="thead"><td align="left">Question/controversy</td><td align="left">Comment</td></tr><tr><td class="thead-hr" colspan="2"><hr/></td></tr><tr><td align="left">Role of lymphadenectomy in low risk</td><td align="left">
								ASTEC trial did not support but results not universally accepted</td></tr><tr><td align="left">Prognostic value of peritoneal cytology</td><td align="left">Removed as a staging variable recently but still to be collected and reported</td></tr><tr><td align="left">Role of radiation in intermediate risk</td><td align="left">Local control improved but no overall survival benefit </td></tr><tr><td align="left">Best adjuvant for high-risk disease</td><td align="left">Recent data supports carboplatin/paclitaxel combination</td></tr><tr><td align="left">Should targeted therapies be utilized</td><td align="left">Further clinical and basic science research required; mTOR inhibtors promising</td></tr><tr class="table-tr"><td colspan="2"><hr class="tbody-hr"/></td></tr></table></td></tr></table>

Selected treatment controversies in endometrial cancer.

Obstetrics and Gynecology International

tab11

Table 11

Table 11: Contemporary Clinical Management of Endometrial Cancer 